Advanced search

Online first
Review paper
Published online: 2024-12-16

open access

View PDF Download PDF file
Page views 49
Article views/downloads 30
Get Citation

Connect on Social Media

Connect on Social Media

The phenomenon of the BRAF and TERTp mutational duet in melanoma and other cancers

DOI: 10.5603/njo.103026

Abstract

The unique oncogenic duo of BRAF and TERT promoter (TERTp) variants was demonstrated to be associated with aggressiveness and poor prognosis in several different cancer types, including melanoma and thyroid cancer. It has been shown that the coexistence of BRAF and TERTp variants has a significantly more substantial impact on clinical outcomes than the presence of mutated BRAF or TERTp alone. At the same time, the co-occurrence of BRAF and TERTp variants may also be the Achilles Heel of cancer cells in the context of targeted therapies’ effectiveness. This paper aims to summarize data from tumors in which clinically significant variants in BRAF and TERTp were documented as prognostic or predictive markers.

Keywords: BRAFTERTpmelanomathyroid cancerglioma

Article available in PDF format

View PDF Download PDF file

References

  1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/melan.html (10.10.2024).
  2. Global Cancer Observatory. https://gco.iarc.who.int/today/en/fact-sheets-populations#countries (10.10.2024).
  3. Saginala K, Barsouk A, Aluru JS, et al. Epidemiology of Melanoma. Med Sci (Basel). 2021; 9(4).
    CrossRefPubMed
  4. Subbiah V, Gouda MA, Ryll B, et al. The evolving landscape of tissue-agnostic therapies in precision oncology. CA Cancer J Clin. 2024; 74(5): 433–452.
    CrossRefPubMed
  5. Bhamidipati D, Schram AM. Emerging Tumor-Agnostic Molecular Targets. Mol Cancer Ther. 2024; 23(11): 1544–1554.
    CrossRefPubMed
  6. Poulikakos PI, Sullivan RJ, Yaeger R. Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clin Cancer Res. 2022; 28(21): 4618–4628.
    CrossRefPubMed
  7. Sarkozy A, Carta C, Moretti S, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat. 2009; 30(4): 695–702.
    CrossRefPubMed
  8. Champion KJ, Bunag C, Estep AL, et al. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. Clin Genet. 2011; 79(5): 468–474.
    CrossRefPubMed
  9. Dankner M, Rose AAN, Rajkumar S, et al. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018; 37(24): 3183–3199.
    CrossRefPubMed
  10. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2): 251–263.
    CrossRefPubMed
  11. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949–954.
    CrossRefPubMed
  12. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005; 12(2): 245–262.
    CrossRefPubMed
  13. Turski ML, Vidwans SJ, Janku F, et al. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther. 2016; 15(4): 533–547.
    CrossRefPubMed
  14. Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017; 548(7666): 234–238.
    CrossRefPubMed
  15. Zaman A, Wu W, Bivona TG. Targeting Oncogenic BRAF: Past, Present, and Future. Cancers (Basel). 2019; 11(8).
    CrossRefPubMed
  16. Chui MH, Shih IM. Oncogenic BRAF and KRAS mutations in endosalpingiosis. J Pathol. 2020; 250(2): 148–158.
    CrossRefPubMed
  17. Udager AM, Pan J, Magers MJ, et al. Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. Am J Surg Pathol. 2015; 39(4): 549–557.
    CrossRefPubMed
  18. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012; 120(13): 2700–2703.
    CrossRefPubMed
  19. Brastianos PK, Santagata S. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol. 2016; 174(4): R139–R144.
    CrossRefPubMed
  20. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003; 33(1): 19–20.
    CrossRefPubMed
  21. McNeal AS, Belote RL, Zeng H, et al. BRAF induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB. Elife. 2021; 10.
    CrossRefPubMed
  22. Marima R, Hull R, Penny C, et al. Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis. Mutat Res Rev Mutat Res. 2021; 787: 108376.
    CrossRefPubMed
  23. Damsky WE, Bosenberg M. Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene. 2017; 36(42): 5771–5792.
    CrossRefPubMed
  24. Lee SJ, Lee MH, Kim DW, et al. Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma. PLoS One. 2011; 6(1): e16180.
    CrossRefPubMed
  25. Fang M, Hutchinson L, Deng A, et al. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. Proc Natl Acad Sci U S A. 2016; 113(5): 1250–1255.
    CrossRefPubMed
  26. HAYFLICK L, MOORHEAD PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961; 25: 585–621.
    CrossRefPubMed
  27. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000; 1(1): 72–76.
    CrossRefPubMed
  28. Colebatch AJ, Dobrovic A, Cooper WA. gene: its function and dysregulation in cancer. J Clin Pathol. 2019; 72(4): 281–284.
    CrossRefPubMed
  29. Yuan X, Larsson C, Xu D. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene. 2019; 38(34): 6172–6183.
    CrossRefPubMed
  30. Thompson CAH, Wong JMY. Non-canonical Functions of Telomerase Reverse Transcriptase: Emerging Roles and Biological Relevance. Curr Top Med Chem. 2020; 20(6): 498–507.
    CrossRefPubMed
  31. Liu Z, Li Q, Li K, et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 2013; 32(36): 4203–4213.
    CrossRefPubMed
  32. Ding D, Xi P, Zhou J, et al. Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-κB-dependent transcription. FASEB J. 2013; 27(11): 4375–4383.
    CrossRefPubMed
  33. Barthel FP, Wei W, Tang M, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017; 49(3): 349–357.
    CrossRefPubMed
  34. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339(6122): 957–959.
    CrossRefPubMed
  35. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339(6122): 959–961.
    CrossRefPubMed
  36. McKelvey BA, Gilpatrick T, Wang Y, et al. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines. Thyroid. 2020; 30(10): 1470–1481.
    CrossRefPubMed
  37. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110(15): 6021–6026.
    CrossRefPubMed
  38. Kinde I, Munari E, Faraj SF, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013; 73(24): 7162–7167.
    CrossRefPubMed
  39. Quaas A, Oldopp T, Tharun L, et al. Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch. 2014; 465(6): 673–677.
    CrossRefPubMed
  40. Shimoi T, Yoshida M, Kitamura Y, et al. TERT promoter hotspot mutations in breast cancer. Breast Cancer. 2018; 25(3): 292–296.
    CrossRefPubMed
  41. Cárcano FM, Vidal DO, van Helvoort Lengert A, et al. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. Tumour Biol. 2016; 37(4): 4901–4907.
    CrossRefPubMed
  42. Nofrini V, Matteucci C, Pellanera F, et al. Activating somatic and germline TERT promoter variants in myeloid malignancies. Leukemia. 2021; 35(1): 274–278.
    CrossRefPubMed
  43. Bell RJA, Rube HT, Xavier-Magalhães A, et al. Understanding TERT Promoter Mutations: A Common Path to Immortality. Mol Cancer Res. 2016; 14(4): 315–323.
    CrossRefPubMed
  44. El Zarif T, Machaalani M, Nawfal R, et al. TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type. Oncologist. 2024; 29(1): 8–14.
    CrossRefPubMed
  45. Vanni I, Tanda ET, Spagnolo F, et al. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. Front Mol Biosci. 2020; 7: 113.
    CrossRefPubMed
  46. Hauschild A, Larkin J, Ribas A, et al. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. JAMA Oncol. 2018; 4(10): 1382–1388.
    CrossRefPubMed
  47. Shinozaki M, O'Day SJ, Kitago M, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res. 2007; 13(7): 2068–2074.
    CrossRefPubMed
  48. Safaee Ardekani G, Jafarnejad SM, Khosravi S, et al. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol. 2013; 169(2): 320–328.
    CrossRefPubMed
  49. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507–2516.
    CrossRefPubMed
  50. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8): 707–714.
    CrossRefPubMed
  51. Long GV, Fung C, Menzies AM, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014; 5: 5694.
    CrossRefPubMed
  52. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372(1): 30–39.
    CrossRefPubMed
  53. Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(4): 364–376.
    CrossRefPubMed
  54. Patel H, Mishra R, Yacoub N, et al. IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Cancers (Basel). 2021; 13(22).
    CrossRefPubMed
  55. Vasudevan S, Flashner-Abramson E, Alkhatib H, et al. Overcoming resistance to BRAF inhibition in melanoma by deciphering and targeting personalized protein network alterations. NPJ Precis Oncol. 2021; 5(1): 50.
    CrossRefPubMed
  56. Hicks HM, Nassar VL, Lund J, et al. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer Biol Ther. 2024; 25(1): 2332000.
    CrossRefPubMed
  57. Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016; 23(3): R143–R155.
    CrossRefPubMed
  58. Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013; 20(4): 603–610.
    CrossRefPubMed
  59. Griewank KG, Murali R, Puig-Butille JA, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst. 2014; 106(9).
    CrossRefPubMed
  60. Gabler L, Lötsch D, Kirchhofer D, et al. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF/TERT promoter double-mutated glioma. Acta Neuropathol Commun. 2019; 7(1): 128.
    CrossRefPubMed
  61. Tavallaee M, Steiner DF, Zehnder JL, et al. Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. Int J Gynecol Pathol. 2019; 38(4): 386–392.
    CrossRefPubMed
  62. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010; 463(7278): 191–196.
    CrossRefPubMed
  63. Macerola E, Loggini B, Giannini R, et al. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch. 2015; 467(2): 177–184.
    CrossRefPubMed
  64. Heidenreich B, Nagore E, Rachakonda PS, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun. 2014; 5: 3401.
    CrossRefPubMed
  65. Liu R, Zhang T, Zhu G, et al. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun. 2018; 9(1): 579.
    CrossRefPubMed
  66. Thielmann CM, Matull J, Zaremba A, et al. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. Eur J Cancer. 2022; 161: 99–107.
    CrossRefPubMed
  67. Bai X, Kong Y, Chi Z, et al. Pathway and Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. Clin Cancer Res. 2017; 23(20): 6120–6127.
    CrossRefPubMed
  68. Song YS, Park YJ. Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E. Endocrinol Metab (Seoul). 2020; 35(3): 515–525.
    CrossRefPubMed
  69. Tan J, Liu R, Zhu G, et al. promoter mutation determines apoptotic and therapeutic responses of -mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proc Natl Acad Sci U S A. 2020; 117(27): 15846–15851.
    CrossRefPubMed
  70. Shen X, Liu R, Xing M. A six-genotype genetic prognostic model for papillary thyroid cancer. Endocr Relat Cancer. 2017; 24(1): 41–52.
    CrossRefPubMed
  71. Rusinek D, Pfeifer A, Krajewska J, et al. Coexistence of Promoter Mutations and the V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients. Int J Mol Sci. 2018; 19(9).
    CrossRefPubMed
  72. Liu J, Liu Y, Lin Y, et al. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy. Endocrinol Metab (Seoul). 2019; 34(3): 215–225.
    CrossRefPubMed
  73. Dunn LA, Sherman EJ, Baxi SS, et al. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. J Clin Endocrinol Metab. 2019; 104(5): 1417–1428.
    CrossRefPubMed
  74. Jafri S, Yaqub A. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib. Cureus. 2021; 13(8): e17488.
    CrossRefPubMed
  75. Su Y, Cheng S, Qian J, et al. Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF Mutations. Front Oncol. 2021; 11: 626076.
    CrossRefPubMed
  76. Song YS, Yoo SK, Kim HH, et al. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer. Endocr Relat Cancer. 2019; 26(6): 629–641.
    CrossRefPubMed
  77. Andrews LJ, Thornton ZA, Saincher SS, et al. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro Oncol. 2022; 24(4): 528–540.
    CrossRefPubMed
  78. Hu WM, Wang F, Xi SY, et al. Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center. J Cancer. 2020; 11(6): 1371–1382.
    CrossRefPubMed
  79. Kaley T, Touat M, Subbiah V, et al. BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol. 2018; 36(35): 3477–3484.
    CrossRefPubMed
  80. Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015; 33(9): 1015–1022.
    CrossRefPubMed
  81. Phillips JJ, Gong H, Chen K, et al. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathol. 2019; 29(1): 85–96.
    CrossRefPubMed
  82. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8): 1231–1251.
    CrossRefPubMed
  83. Razis E, Kotoula V, Koliou GA, et al. Is There an Independent Role of TERT and NF1 in High Grade Gliomas? Transl Oncol. 2020; 13(2): 346–354.
    CrossRefPubMed
  84. Vuong HG, Altibi AMA, Duong UNP, et al. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. Crit Rev Oncol Hematol. 2017; 120: 1–9.
    CrossRefPubMed
  85. Terzi NK, Yilmaz I, Oz AB. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas. Turk Patoloji Derg. 2022; 38(2): 90–98.
    CrossRefPubMed
  86. Koelsche C, Sahm F, Capper D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013; 126(6): 907–915.
    CrossRefPubMed
  87. Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003; 95(6): 484–486.
    CrossRefPubMed
  88. Jones S, Wang TL, Kurman RJ, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012; 226(3): 413–420.
    CrossRefPubMed
  89. Grisham RN, Iyer G, Garg K, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013; 119(3): 548–554.
    CrossRefPubMed
  90. Anglesio MS, Arnold JM, George J, et al. AOCS Study Group. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res. 2008; 6(11): 1678–1690.
    CrossRefPubMed
  91. Moujaber T, Etemadmoghadam D, Kennedy CJ, et al. Australian Ovarian Cancer Study. Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precis Oncol. 2018; 2: 1–14.
    CrossRefPubMed
  92. Kobayashi H, Zhang L, Okajima K, et al. BRAF mutations and concurrent alterations in patients with soft tissue sarcoma. Genes Chromosomes Cancer. 2023; 62(11): 648–654.
    CrossRefPubMed
  93. Protsenko SA, Semionova AI, Komarov YI, et al. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Invest New Drugs. 2015; 33(5): 1136–1143.
    CrossRefPubMed
  94. Watanabe S, Shimomura A, Kubo T, et al. BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma. Mod Pathol. 2020; 33(9): 1660–1668.
    CrossRefPubMed
  95. Liu H, Nazmun N, Hassan S, et al. BRAF mutation and its inhibitors in sarcoma treatment. Cancer Med. 2020; 9(14): 4881–4896.
    CrossRefPubMed
  96. Lucchesi C, Khalifa E, Laizet Y, et al. Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy. JAMA Oncol. 2018; 4(10): 1398–1404.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note